Apolipoprotein B as a long‐term predictor of mortality in type 1 diabetes mellitus: a 15‐year follow up

Objectives.  To evaluate the association of apolipoprotein B (apo B) with mortality due to all causes, to cardiac disease and to ischaemic heart disease (IHD) in subjects with type 1 diabetes mellitus.

[1]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[2]  S. Lipsitz,et al.  Immune complexes containing modified lipoproteins are related to the progression of internal carotid intima-media thickness in patients with type 1 diabetes. , 2007, Atherosclerosis.

[3]  Peter Jüni,et al.  Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials. , 2006, American heart journal.

[4]  J. Danesh,et al.  Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature‐based meta‐analysis of prospective studies , 2006, Journal of internal medicine.

[5]  C. Packard,et al.  Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels , 2006, Journal of internal medicine.

[6]  P. Durrington,et al.  Apolipoproteins AI and B as therapeutic targets , 2006, Journal of internal medicine.

[7]  O. Faergeman.  Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease , 2006, Journal of internal medicine.

[8]  A. Biggeri,et al.  Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study , 2006, Diabetologia.

[9]  R. Krauss,et al.  Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel , 2006, Journal of internal medicine.

[10]  A. Gotto,et al.  The evolution of European guidelines: changing the management of cholesterol levels. , 2006, Atherosclerosis.

[11]  S. Soedamah-Muthu,et al.  All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992–1999 , 2006, Diabetologia.

[12]  Nader Rifai,et al.  Non–High-Density Lipoprotein Cholesterol and Apolipoprotein B in the Prediction of Coronary Heart Disease in Men , 2005, Circulation.

[13]  L. Lind,et al.  The Apolipoprotein B/AI Ratio and the Metabolic Syndrome Independently Predict Risk for Myocardial Infarction in Middle-Aged Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[14]  N. Cook,et al.  Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. , 2005, JAMA.

[15]  R. Bayoumi,et al.  A potential role of apolipoprotein B in the risk stratification of diabetic patients with dyslipidaemia. , 2005, Diabetes research and clinical practice.

[16]  P. Gambert,et al.  Normal metabolism of apolipoprotein B100-containing lipoproteins despite qualitative abnormalities in type 1 diabetic men , 2005, Diabetologia.

[17]  G. Dagenais,et al.  Low-Density Lipoprotein Subfractions and the Long-Term Risk of Ischemic Heart Disease in Men: 13-Year Follow-Up Data From the Québec Cardiovascular Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[18]  J. Manson,et al.  Joint role of non-HDL cholesterol and glycated haemoglobin in predicting future coronary heart disease events among women with type 2 diabetes , 2004, Diabetologia.

[19]  A. Moss,et al.  Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. , 2004, Atherosclerosis.

[20]  J. Manson,et al.  Multivariate Assessment of Lipid Parameters as Predictors of Coronary Heart Disease Among Postmenopausal Women: Potential Implications for Clinical Guidelines , 2004, Circulation.

[21]  S. Haffner,et al.  Comparison of the Associations of Apolipoprotein B and Non–High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study , 2004, Circulation.

[22]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[23]  John H Fuller,et al.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.

[24]  Nader Rifai,et al.  Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. , 2004, Diabetes care.

[25]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[26]  D. Lackland,et al.  Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. , 2004, Investigative ophthalmology & visual science.

[27]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2004, European heart journal.

[28]  R. McPherson,et al.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[29]  P. Diem,et al.  Effects of alcohol consumption on mortality in patients with Type 2 diabetes mellitus , 2003, Diabetologia.

[30]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[31]  D. Lackland,et al.  Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. , 2003, Kidney international.

[32]  S. Love,et al.  Survival Analysis Part II: Multivariate data analysis – an introduction to concepts and methods , 2003, British Journal of Cancer.

[33]  A. Wägner,et al.  Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. , 2003, Diabetes care.

[34]  A. Keech,et al.  Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment , 2003, The Lancet.

[35]  J. Mckenney,et al.  National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .

[36]  S. Grundy.  Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. , 2002, Circulation.

[37]  E. Hawe,et al.  Nonfasting Apolipoprotein B and Triglyceride Levels as a Useful Predictor of Coronary Heart Disease Risk in Middle-Aged UK Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[38]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[39]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study☆ , 2002 .

[40]  A. Keech,et al.  Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels? , 2002, Circulation.

[41]  J. Frohlich,et al.  Hypertriglyceridemic hyperapoB in type 2 diabetes. , 2002, Diabetes care.

[42]  I. Holme,et al.  High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study , 2001, The Lancet.

[43]  M. Taskinen,et al.  Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes. , 2001, Diabetes Care.

[44]  P. Carroll,et al.  Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus , 2001, Clinical endocrinology.

[45]  G. Watts,et al.  Long-term predictors of coronary artery disease and mortality in type 1 diabetes. , 2001, QJM : monthly journal of the Association of Physicians.

[46]  A. Sniderman,et al.  Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus , 2001, Annals of Internal Medicine.

[47]  D R Shapiro,et al.  Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). , 2000, Circulation.

[48]  G. Thorgeirsson,et al.  Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.

[49]  R. James,et al.  Differences in Lipoprotein Subfraction Composition and Distribution Between Type I Diabetic Men and Control Subjects , 1990, Diabetes.

[50]  J. Herman,et al.  [Vascular diseases in 534 Swiss diabetics within the scope of a multinational study]. , 1983, Klinische Wochenschrift.

[51]  H. Keen,et al.  The WHO Multinational Study of Vascular Disease in Diabetes: 1. General Description , 1979, Diabetes Care.

[52]  A. Teuscher,et al.  Vaskuläre Erkrankungen bei 534 Schweizer Diabetikern im Rahmen einer multinationalen Studie , 2005, Klinische Wochenschrift.

[53]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[54]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[55]  M. Taskinen,et al.  The EURODIAB Prospective Complications Study Group. Differing associations of lipid and lipoprotein disturbances with the macrovascular and microvascular complications of type 1 diabetes , 2001 .